Tag: mantle cell lymphoma

REDLAMP 15: Outcomes for Patients with Mantle Cell Lymphoma after Ibrutinib

While ibrutinib represents undeniable progress in the treatment of mantle cell lymphoma, the outcomes and ideal management of patients that experience ibrutinib failure are unclear. In a study recently published in Blood, Dr. Peter Martin discusses findings from a recent observational study from 15 sites on patients who experienced lymphoma progression while receiving ibrutinib.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Dr. Peter Martin Discusses Transplantation as a Treatment Option for Patients with Mantle Cell Lymphoma

In an interview with the Lymphoma Research Foundation (LRF), Dr. Peter Martin discusses mantle cell lymphoma (MCL), treatment options including transplantation, and what advice he would give to people who are newly diagnosed with MCL.

Debate exists among researchers on whether or when stem cell transplantation should be used in the treatment of MCL. Why do you think this is so?

…

“Some people feel that stem cell transplantation is likely to make a patient live longer and others feel that a long remission duration following a stem cell transplant means there are fewer lymphoma-related side effects, and everybody likes that idea.

On the other hand, autologous stem cell transplantation doesn’t cure MCL. There are limited data that suggest that it may allow people to live longer, and many patients may experience significant side effects but not have a very durable remission and a longer life. So that’s a very subjective sort of decision based on less than perfect evidence.

It’s our job as lymphoma doctors to help patients understand the potential benefits and the potential negative side effects to all treatment options so they can select a treatment that is best for them. There’s no right or wrong treatment option in many cases and it’s a matter of choosing the option that makes the most sense for that person at that point in time.”

The full interview can be read on the LRF’s website.

Ibrutinib—A New Standard Treatment for Mantle Cell Lymphoma?

In The Lancet, Dr. Peter Martin commented on the results of a recently completed phase 3 trial in Europe that compared ibrutinib to temsirolimus among patients with mantle cell lymphoma. He writes that the results of the study clearly establish, “…ibrutinib as a new standard for treatment of relapsed mantle cell lymphoma.” Dr. Martin’s full comments on the topic can be found in the attached PDF below:

Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?

A full listing of currently available clinical trials for mantle cell lymphoma can be found on the Joint Clinical Trials website.